Analyzing Dimension Therapeutics (DMTX) and The Competition
Dimension Therapeutics (NASDAQ: DMTX) is one of 284 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Dimension Therapeutics to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, institutional ownership, dividends and profitability.
This table compares Dimension Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dimension Therapeutics Competitors||-5,592.19%||-432.91%||-40.69%|
Institutional and Insider Ownership
70.3% of Dimension Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.2% of Dimension Therapeutics shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for Dimension Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dimension Therapeutics Competitors||809||3181||11525||230||2.71|
Dimension Therapeutics presently has a consensus price target of $5.08, suggesting a potential downside of 14.59%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.82%. Given Dimension Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Dimension Therapeutics has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares Dimension Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Dimension Therapeutics||$11.47 million||-$49.00 million||-2.67|
|Dimension Therapeutics Competitors||$286.20 million||$34.74 million||138.68|
Dimension Therapeutics’ rivals have higher revenue and earnings than Dimension Therapeutics. Dimension Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Dimension Therapeutics rivals beat Dimension Therapeutics on 8 of the 11 factors compared.
About Dimension Therapeutics
Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.